<DOC>
	<DOCNO>NCT00136110</DOCNO>
	<brief_summary>The purpose study determine whether use sodium valproate effective slow disease progression Amyotrophic Lateral Sclerosis .</brief_summary>
	<brief_title>Trial Sodium Valproate Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description>Amyotrophic lateral sclerosis ( ALS ) devastate disease characterize progressive degeneration motor neuron lead muscle weakness . The pathogenesis ALS unknown , convincing evidence several molecular mechanism play role . Previous study investigate role Survival Motor Neuron ( SMN ) gene ALS . Recent data suggest SMN genotypes produce less SMN protein increase susceptibility severity ALS . This lead hypothesis clinical expression ALS influence total SMN protein level affect patient . In population ALS patient Netherlands find SMN genotype produce less SMN protein appear increase susceptibility severity ALS . It show HDAC inhibitor sodium valproate ( SVP ) increase level SMN protein vitro . From result data suggest neuroprotective property SVP , hypothesise SVP could extend survival patient ALS . In addition , sodium valproate significantly prolong disease duration animal model ALS , SOD1 transgenic mouse . Given SVP FDA-approved compound well-known pharmacokinetic toxicity profile , attractive candidate clinical trial ALS patient .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>Definite , probable , probablelaboratory support ALS accord revise El Escorial World Federation Neurology criterion . Intake riluzole 50 mg twice day ( bid ) A disease duration inclusion 6 month le 36 month [ inclusive ] ( disease onset define date first symptoms exclude muscle cramp fasciculation ) Vital capacity ( VC % ) â‰¥ 70 % normal value ( slow expiration , best minimum three maximum five measurement , respiratory function validly assessable spontaneous , nonassisted ventilation ) Ages 18 85 year ( inclusive ) Capable thoroughly understand trial information give ; sign informed consent . Tracheostomy , tracheostomal ventilation type , noninvasive ventilation 16 hours/ day , supplemental oxygen last three month prior inclusion . Any medical condition intoxication know association motor neuron dysfunction , might confound obscure diagnosis ALS . Presence concomitant lifethreatening disease disease impairment likely interfere functional assessment . Confirmed hepatic insufficiency abnormal liver function ( ASAT , ALAT great twice upper limit normal range ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>ALS</keyword>
	<keyword>Sodium Valproate</keyword>
	<keyword>randomise trial</keyword>
	<keyword>Amyotrophic Lateral Sclerosis ( ALS )</keyword>
</DOC>